AGGRESSIVELY
TARGETING
CANCER
REIMAGINING T-CELL
ENGINEERING
to unlock the promise of immunotherapy

A treatment approach
with the potential to transform patient outcomes

Vittoria Biotherapeutics is a clinical-stage company with a novel platform technology, Senza5, that powers a pipeline of highly differentiated immunotherapies designed to address unmet clinical needs in oncology and immunology.
Next-generation CAR T-cell therapy

NEXT-GENERATION, ENABLED-AUTOLOGOUS CAR T-CELL THERAPIES

Our therapies are being developed with a goal of improving efficacy, safety, and accessibility.

Proprietary
SENZA5™ platform
technology

Unprecedented utility and superior potency are achieved by CD5 signaling modulation and a novel 5-day manufacturing process.

Senza5 for differentiated, enabled autologous cell therapy

CLINICAL TRIAL
RECRUITING NOW

Our VIPER-101 Phase 1 trial for the treatment of T-cell lymphoma is currently enrolling participants (NCT06420089).

News

NOVEMBER 25, 2024
Vittoria Biotherapeutics Announces Oral and Poster Presentations at the 66th American Society of Hematology (ASH) Annual Meeting
NOVEMBER 12, 2024
Vittoria Biotherapeutics Completes $25 Million in Private Financing to Propel Groundbreaking Cell Therapy Candidates
JULY 22, 2024
Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology